CoChat

Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

Open access
Gheorghiade, Mihai, Albaghdadi, Mazen, Zannad, Faiez, Fonarow, Gregg C., Böhm, Michael, Gimpelewicz, Claudio, Botha, Jaco, Moores, Shelley, Lewis, Eldrin F., Rattunde, Henning, Maggioni, Aldo · 2011 · European Journal of Heart Failure
Cited by 78

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Hospitalizations for acute heart failure syndromes (AHFS) are associated with high post-discharge mortality and readmission rates in spite of available therapies. Renin–angiotensin–aldosterone system (RAAS) antagonists improve outcomes in outpatients with heart failure (HF) and reduced ejection fraction, however these therapies have not been tested in AHFS. Aliskiren is a direct renin inhibitor (DRI) that is known to enhance RAAS inhibition, which may result in improved clinical outcomes in AHFS. The aim of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) study is to evaluate the effect of aliskiren on cardiovascular death and HF in AHFS patients. Methods: ASTRONAUT will be an event-driven trial with an estimated enrolment of 1782 patients hospitalized with worsening chronic HF, a left ventricular ejection fraction ≤40%, and an estimated glomerular filtration rate ≥40 mL/min/1.73 m2. Patients will be randomized 1:1 in a double-blind fashion to receive aliskiren or placebo, in addition to standard HF therapy. The primary endpoint will be a composite of time to either cardiovascular death or first occurrence of HF re-hospitalization. Perspective: Aliskiren is a DRI with a favourable neurohormonal and haemodynamic profile that may benefit patients hospitalized with worsening HF. Given the neurohormonal abnormalities that are present during and after hospitalization for AHFS, it is hypothesized that adding aliskiren to standard therapy will reduce post-discharge mortality and re-hospitalization. NCT00894387.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfq209

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 78

Metadata

Authors
Gheorghiade, M., Albaghdadi, M., Zannad, F., Fonarow, G. C., Böhm, M., Gimpelewicz, C., Botha, J., Moores, S., Lewis, E. F., Rattunde, H., & Maggioni, A.
Venue
European Journal of Heart Failure
Published
2011-01-01
Volume
13
Issue
1
Pages
100-106
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2059356953
Cited by
78
References
3
FWCI
10.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). https://app.cochat.ai/papers/10.1093/eurjhf/hfq209
The paper
Gheorghiade, M., Albaghdadi, M., Zannad, F., Fonarow, G. C., Böhm, M., Gimpelewicz, C., Botha, J., Moores, S., Lewis, E. F., Rattunde, H., & Maggioni, A. (2011). Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.